Simulations Plus, a model-informed drug-development software firm that now calls Research Triangle Park home, has signed a deal to be acquired by healthcare investment firm Altaris in an all-cash transaction valued at about $375 million. If the merger closes, Simulations Plus will go private and its common stock will disappear from the Nasdaq.
Inside the Deal
Altaris has agreed to pay $18.50 per share in cash, roughly a 26% premium to the company's recent trading average. The Simulations Plus board signed off on the agreement unanimously. The two sides are aiming to close in the fourth quarter of 2026, pending stockholder approval and the usual regulatory sign-offs, according to The Business Journals.
Headquarters and Jobs
Simulations Plus shifted its headquarters from Lancaster, California, to Research Triangle Park in 2025 and has been growing its local footprint ever since. As of August 31, 2025, the company reported 213 employees in its Form 10-K, which lists the RTP address as its headquarters.
Altaris's Playbook
Altaris says it plans to combine Simulations Plus with Chemical Computing Group, another company in its portfolio, to build out a larger platform for computational chemistry and AI-driven drug-discovery software. Despite the ownership change, Simulations Plus is slated to remain headquartered in RTP after the deal, a point underscored by CityBiz.
What It Means for the Triangle
The transaction pulls one of the Triangle's public companies off the stock market not long after it officially moved its base to the region, a shift the local business press has flagged as meaningful for investors and the broader life-sciences ecosystem. At the same time, Altaris's promise to keep the headquarters in RTP helps blunt the immediate risk to local jobs and vendor relationships, though observers say they will be watching to see if operations are gradually consolidated elsewhere over the longer term, as covered by The Business Journals.
Next Steps and Approvals
The merger agreement includes a voting and support arrangement with co-founder Dr. Walter Woltosz and is backed by committed equity and debt from Altaris affiliates, with the company stating there is no financing contingency. The deal still requires approval from Simulations Plus shareholders and regulatory authorities, and both parties say they expect to wrap things up in the fourth quarter of 2026, per the company's Form 8-K.
About Simulations Plus
Simulations Plus develops software including GastroPlus, ADMET Predictor and MonolixSuite, tools used by pharmaceutical companies to model how drugs are absorbed, how toxic they might be and how they behave in the body. The company plans to report its third-quarter fiscal 2026 results on July 9 but has said it will not host an earnings call while the Altaris transaction is pending, according to corporate materials on Simulations Plus.
